TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Topical Silver for Prevention of Wound Infection After Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cesarean delivery with pfannenstiel incision~Exclusion Criteria:~* Incision other than pfannenstiel~* Silver allergy~* Inability to provide informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Silver-containing surgical dressing (Type: ACTIVE_COMPARATOR): Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
- Cloth adhesive dressing (Type: ACTIVE_COMPARATOR): Soft cloth adhesive wound dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children ages 7 to \<19~* Acute vaso-occlusive crisis~* Persistent pain despite initial pain management with intravenous (IV) opioids~Exclusion Criteria:~* Contraindications to the use of ketamine~* Mental retardation or psychological conditions that may affect the proper evaluation of pain and side effects~* Known allergy to ketamine

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants ages 2-15 years~* Documented detrusor overactivity associated with a known neurological condition such as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline~* Using clean intermittent catheterization (CIC) on a regular basis~* Participating in a bowel program on a regular basis~* Able to swallow the study medication in accordance to the protocol~* Participants and/or parent/guardian able to complete the bladder diary and follow the study procedures~Exclusion Criteria:~* Treatment with drugs known to significantly affect the urinary bladder and urinary bladder outlet function~* Fecal impaction. Participants may be included, once this condition has resolved~* Clinically significant anatomical abnormalities or acquired disorders of the urinary tract~* Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet~* Symptomatic urinary tract infection unresolved at time of urodynamic study and/or completion of bladder diary.~* Diabetes insipidus~* Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at any time during the study~* Concomitant diseases, in which the use of darifenacin is contraindicated~* History of hypersensitivity to darifenacin or to drugs with similar chemical structures~* Participants with any physical and cognitive impairment or any other condition which in the opinion of the investigator makes the participants unsuitable for inclusion~* Female adolescent of child-bearing potential, unless using an acceptable method of contraception~* Pregnant or nursing (lactating) female adolescents Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Darifenacin 0.030 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.030 milligrams/kilogram/day (mg/kg/day) dispensed per twice a day (BID) dosing, for 14 days.
- Cohort 2 (Darifenacin 0.0625 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.0625 mg/kg/day dispensed per BID dosing, for 14 days.
- Cohort 3 (Darifenacin 0.125 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.125 mg/kg/day dispensed per BID dosing, for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Pap Smear Derived Cells to Analyze the Expression of SLC6A14 and GPR81 Genes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Women who present to the TTUHSC Lubbock OBGYN Clinics for exams and are having cervical Pap smear collected as part of the evaluations.~2. Women who have vaginal discharge will be also included in the study if they are having cervical Pap smear collected as part of their exam.~3. Age criteria 21yr- 65yrs or more -per ASCCP guidelines for Pap smears.~4. Patients on any medications will also be included- medications have no effect on Pap smear results.~Exclusion Criteria:~1. Women who have had a hysterectomy.~2. Women having vaginal Pap smears.~3. Women with known HIV.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Normal Pap smears (Type: None): This is the control group.
- Abnormal Pap smears (Type: None): This is the case group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of in Vivo Mitochondrial Capacity in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* healthy, full-term infant~* aged 14-28 days at Visit 1~* willingness of parents to be notified of incidental findings from study procedures~Exclusion Criteria:~* born preterm~* implanted metal or electronic objects that render MRI unsafe~* unable to complete 2 clinic visits 1-10 days apart at Pennington Biomedical Research Center

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodynamically stable, as determined by the trauma team~* Age 8 through 17 years~* Interpretable CT of the abdomen and pelvis that demonstrates at least one abdominal solid organ injury among the liver, spleen, pancreas, and kidneys~* Plan for observation or admission to the hospital~* Candidate for abdominal ultrasound based on body habitus~* Have a Glasgow Coma Score of 15~* Able to complete the study procedures within 48 hours of injury~Exclusion Criteria:~* Known cardiac abnormality~* Pulmonary hypertension~* Known sensitivity to sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid~* Unable to roll over~* Unable to assent~* Pregnant~* Lactating~* CT images not available for transmission to central image repository

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- All Study Participants (Type: EXPERIMENTAL): All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients from 10 years of age with \<5 days of abdominal pain and suspicion of appendicitis~Exclusion Criteria:~* pregnant women, children \<10 years of age

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic imaging (Type: EXPERIMENTAL): Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
- Repeat examination after observation (Type: ACTIVE_COMPARATOR): Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Renal transplant patient's aged between 18 and 60 years old.~2. Heart rate in radial pulse and seated between 50 and 100 bpm.~3. Systolic blood pressure between 100 and 140 and diastolic between 50 to 90.~4. Absence of any clinical physical, psychological or psychiatric condition that would prevent from the protocol described follow-up.~5. Estimated glomerular filtration rate greater than 40 ml / min.~6. Proteinuria \< 0.5 g / d.~7. Renal transplantation at least 6 months ago.~8. Immunosuppressant based on calcineurin inhibitors.~9. Hemoglobin \> 11 g / dl.~10. Body mass index (BMI) \< 35 kg/m2.~11. Indication for conversion to everolimus and granting of written informed consent.~Exclusion Criteria:~1. Diabetes mellitus~2. Treatment with erythropoiesis stimulating drugs~3. Treatment with β blockers drugs~4. Participation in any clinical trial in the last 30 days prior to the inclusion.~5. Any other physical illness, psychological or psychiatric condition that could difficult the follow-up of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Is 18 years of age or older.~Is experiencing the following:~1. Newly diagnosed MM within 3 months from initiation of treatment with documented month and year of diagnosis, criteria met for diagnosis, stage, and MM-directed treatment history, including duration, or~2. Relapsed/refractory MM who have received 1 to 3 prior lines of therapy with documented data in the medical record regarding diagnosis (month and year), the regimens used in 1st, 2nd, and 3rd line as applicable, whether stem cell transplant was part of 1st, 2nd, and 3rd line of therapy, whether consolidation/maintenance was part of 1st, 2nd, and 3rd line of therapy, also whether investigational therapy/treated on a clinical trial was part of any of these regimens.~Is willing and able to sign informed consent to participate. Is willing and able to complete patient-reported outcomes (PROs) in accordance with local regulatory and data protection requirements.~Exclusion Criteria:~Is reporting to a site in this study for a second opinion (consultation only) or participants whose frequency of consult and follow-up are not adequate for quarterly electronic case report form (eCRF) completion.~Has participated in another study (observational or interventional) that prohibits participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relapsed/refractory (R/R) MM (Type: None): Patients who have received 1 to 3 prior lines of therapy
- Newly diagnosed (ND) MM (Type: None): Patients within 3 months from initiation of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of A Novel Enteral Feeding System: Prospective Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with Gastrostomy (G) tube or Jejunostomy (J) tubes~* Participant must require enteral tube feeding every day, as determined at the time of study enrolment~* Participant must use commercially available enteral formula with standard enteral feeding system(s) (gravity bag, bolus, pump or combination(s)), for some or all of their tube feeds, for daytime or day and night-time feeding~* Participant must be EN dependent i.e., 500 ml minimum daily feed intake from EN~* Participants must be able to swap from current system to Mobility+ for a minimum of two daily feeds per day for duration of study (Study days 1 -14)~* Participant must be \>= 18 to reflect the subset of the intended use population being evaluated~* Participant must be willing to participate in the study and provide consent).~* Participants must have been on an enteral feeding regime for a minimum of 10 weeks~* Participants clinical functional capacity is adequate as determined by operator clinical judgement, to enable them to participate fully in the study~* Participants are suitable candidates for using Mobility+ as determined by operator clinical judgement on participant enteral feeding needs (as per prescription) and alignment with Mobility+ Flow Rate Guide~Exclusion Criteria:~* Participants who do not use commercially available enteral formula for some or all their formula needs~* Participants unable/unwilling to provide consent~* Participants whose enteral feeding needs do not match the offering of the Mobility+, as determined by operator clinical judgement~* Participants who have inadequate clinical functional capacity, as determined by operator clinical judgement to participate fully in the study e.g. neuromuscular or neurodegenerative disorders, or developmental delay~* Participants with very limited mobility, as determined by operator clinical opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mobility+ Arm (Type: EXPERIMENTAL): Adult patients using Mobility+ novel enteral feeding system for nutritional intake.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Do the Head-elevated Position and the Use of a Videolaryngoscope Facilitate Orotracheal Intubation in a Patient Population Without Predictable Difficulty of Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 - 89 years old~* Scheduled for elective surgical procedures~* Requiring oro-tracheal intubation for general anesthesia~* Having a telephone and agreeing to communicate their phone number in case of ambulatory surgery~* Having signed an informed consent form~* Benefiting from a social insurance~Exclusion Criteria:~* Pregnant or breast-feeding women~* Patients with an anticipated difficult mask ventilation or an anticipated difficult intubation (Arné's score ≥ 11)~* Patients scheduled for a surgical procedure involving the mouth or the upper airway~* Patients requiring a rapid induction sequence, the use of a double-lumen tube~* Patients having a contra-indication to one of the drug administered by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Without RAMP and without video (Type: EXPERIMENTAL): Sniffing position and a standard Macintosh laryngoscope
- With RAMP and with video (Type: EXPERIMENTAL): Ramped position and a McGrath Mac videolaryngoscope
- Without RAMP and with video (Type: EXPERIMENTAL): Sniffing position and a McGrath Mac videolaryngoscope
- With RAMP and without video (Type: EXPERIMENTAL): Ramped position and a standard Macintosh laryngoscope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic osseous bone lesion(s) from any malignancy, whether primary of metastatic, with histological confirmation of malignancy.~* Currently enrolled in hospice and referred for single fraction palliative radiotherapy.~* Performance status (to be evaluated by the radiation oncologist), Karnofsky Performance Scale ≥ 20 or ECOG Performance Scale \< 5 .~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Pregnancy.~* Unable to understand English.~* Unable to complete forms with assistance.~* Concurrent enrollment in a study of pain management involving medications or devices.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (radiation therapy) (Type: EXPERIMENTAL): This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients will be men or women, between 18 and 75 years old.~* Patients must have been taken an stable dosis of Angiotensine Converter Enzyme Inhibitor, Angiotensine Receptor Antagonism or antialdosterone at last 6 months before screening visit.~* Patients should not be on dialysis treatment.~* Women should not be pregnant, or in fertile period (at last 1 year postmenopausal or chirurgic sterilized or using this contraceptive methods: condoms, gel, intrauterine devices, anticonceptives, etc. During at last 3 months after the study beginning.~Exclusion Criteria:~* Patients have taken active vitamin D during 6 months after the screening.~* Patients with allergy o sensibility to paricalcitol.~* Patients with acute CKD 12 weeks before the screening.~* Patients with chronical gastrointestinal disease.~* Patients with hypo or hyperthyroidism.~* Patients with secondary hypertension~* Bad controled hypertension patients~* Patients with renal lithiasis~* Patients with drug dependence~* Patients taking calcitonins, biphosphonates, cinacalcet or others Ca-metabolism drugs.~* Patients taking immunosuppressor drugs.~* Patients not adequate to study as medical opinion.~* HIV patients~* Seric P \> 5.0 mg/dl.~* Seric Ca\> 10,0 mg/dl.~* Proteinuria \> 3.500 mg/g~* Hypoalbuminemia \< 3g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol, Daily treatment, CKD (Type: EXPERIMENTAL): Experimental Arm
- Daily treatment for CKD (Type: OTHER): Comparator Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues